Skip to main content
SpringerLink
Log in

Current Management of Peripheral Arterial Occlusive Disease

A Review of Pharmacologic Agents and Other Interventions

  • Therapy in Practice
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Peripheral arterial occlusive disease (PAOD) of the lower extremities is becoming more prevalent worldwide. Nonsurgical treatment options provide the foundation for management. Lifestyle and risk factor modification should be emphasized in this patient population because of the associated adverse cardiovascular events. This includes implementation of a regular walking and smoking-cessation programs, aggressive control of hyperlipidemia, hypertension and diabetes mellitus, and treatment of hyperhomocysteinemia. Antiplatelet agents such as aspirin (acetylsalicylic acid) or clopidogrel are not specifically indicated for claudication but these drugs should be used in all patients with PAOD to prevent secondary ischemic events. Currently, cilostazol is the only US FDA approved agent that appears effective for the treatment of claudication symptoms. Several agents have been used with success outside of the US and others are still undergoing testing. Definitive recommendations cannot be made on the use of these drugs until further evaluation is completed. Ongoing research with new strategies for angiogenesis and the use of progenitor cells has yielded encouraging results, particularly for patients with critical limb ischemia and limited options. Advances in endovascular technology over the last several years have greatly enhanced the ability to diagnose and treat specific anatomic lesions that previously would have required open surgical correction. The use of percutaneous transluminal angioplasty and stents in the lower extremities has had considerable success when following specific guidelines such as those set forth by the TransAtlantic Inter-Society Consensus Working Group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608–21.

    Article  PubMed  CAS  Google Scholar 

  2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Vasc Interv Radiol 2006; 17: 1383–98.

    Article  PubMed  Google Scholar 

  3. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC Working Group. Trans-Atlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1–S296.

    Article  PubMed  CAS  Google Scholar 

  4. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg 2002; 36: 1283–91.

    Article  PubMed  Google Scholar 

  5. Retiring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005; 41: 816–22.

    Article  Google Scholar 

  6. McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144: 10–20.

    PubMed  Google Scholar 

  7. Zwierska I, Walker RD, Choksy S, et al. Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a randomized controlled trial. J Vasc Surg 2005; 42: 1122–30.

    Article  PubMed  Google Scholar 

  8. Treesak C, Kasemsup V, Treat-Jacobson D, et al. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med 2004; 9: 279–85.

    Article  PubMed  Google Scholar 

  9. Dean SM. Pharmacologic treatment for intermittent claudication. Vasc Med 2002; 7: 301–9.

    Article  PubMed  Google Scholar 

  10. Dawson DL, Zheng Q, Worthy SA, et al. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002; 53: 509–20.

    Article  PubMed  Google Scholar 

  11. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blinded trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66–72.

    Article  PubMed  CAS  Google Scholar 

  12. Lindgarde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease: Scandinavian Study Group. Circulation 1989; 80: 1549–56.

    Article  PubMed  CAS  Google Scholar 

  13. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155: 1053–9.

    PubMed  CAS  Google Scholar 

  14. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159: 337–45.

    Article  PubMed  CAS  Google Scholar 

  15. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523–30.

    Article  PubMed  CAS  Google Scholar 

  16. Elam MB, Heckman JR, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18: 1942–7.

    Article  PubMed  CAS  Google Scholar 

  17. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20: 900–6.

    Article  PubMed  CAS  Google Scholar 

  18. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678–86.

    Article  PubMed  CAS  Google Scholar 

  19. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267–75.

    Article  PubMed  CAS  Google Scholar 

  20. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041–50.

    Article  PubMed  CAS  Google Scholar 

  21. Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized double-blind, placebo-controlled study. Vasc Endovascular Surg 2002; 36: 83–91.

    Article  PubMed  Google Scholar 

  22. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991; 325: 1468–75.

    Article  PubMed  CAS  Google Scholar 

  23. Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108: 1481–6.

    Article  PubMed  CAS  Google Scholar 

  24. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114: 359–64.

    Article  PubMed  CAS  Google Scholar 

  25. Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92: 711–2.

    Article  PubMed  CAS  Google Scholar 

  26. Trubestein G, Bohme H, Heidrich H, et al. Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study. Angiology 1984; 35: 701–8.

    Article  PubMed  CAS  Google Scholar 

  27. Adhoute G, Andreassian B, Boccalon H, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990; 16: S75–80.

    PubMed  Google Scholar 

  28. Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23: S44–7.

    PubMed  Google Scholar 

  29. Lehert P, Conte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994; 23: S48–52.

    PubMed  Google Scholar 

  30. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159: 337–45.

    Article  PubMed  CAS  Google Scholar 

  31. Trübestein G, Balzer K, Bisler H, et al. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984; 35: 500–5.

    Article  PubMed  Google Scholar 

  32. PACK Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Circulation 1989; 80: 1544–8.

    Article  Google Scholar 

  33. Picano E, Testa R, Pogliani M, et al. Increase of walking capacity after acute aminophylline administration in intermittent claudication. Angiology 1989; 40: 1035–9.

    Article  PubMed  CAS  Google Scholar 

  34. Hiatt WR, Wolfel EE, Regensteiner JG, et al. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992; 73: 346–53.

    PubMed  CAS  Google Scholar 

  35. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double blind, cross-over study. Circulation 1988; 77: 767–73.

    Article  PubMed  CAS  Google Scholar 

  36. Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995; 26: 1411–6.

    Article  PubMed  CAS  Google Scholar 

  37. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618–24.

    Article  PubMed  CAS  Google Scholar 

  38. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110: 616–22.

    Article  PubMed  CAS  Google Scholar 

  39. Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336–44.

    Article  PubMed  CAS  Google Scholar 

  40. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 2000; 5: 11–9.

    PubMed  CAS  Google Scholar 

  41. Diehm C, Balzer K, Bisler H, et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. J Vasc Surg 1997; 25: 537–44.

    Article  PubMed  CAS  Google Scholar 

  42. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 2005; 56: 409–15.

    Article  PubMed  Google Scholar 

  43. Lievre M, Morand S, Besse B, et al. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102: 426–31.

    Article  PubMed  CAS  Google Scholar 

  44. UK Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. Eur J Vasc Surg 1991; 5: 511–6.

    Article  Google Scholar 

  45. Mohler III ER, Hiatt WR, Olin JW, et al. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin 12 analogue, a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41: 1679–86.

    Article  PubMed  CAS  Google Scholar 

  46. Mikiko M, Masazumi W, Hitoshi F, et al. The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study. Ann Vasc Surg 2005; 19: 838–42.

    Article  Google Scholar 

  47. Rajagopalan S, Mohler III ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933–8.

    Article  PubMed  CAS  Google Scholar 

  48. Lederman RJ, Mendelsohn FO, Anderson DR, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053–8.

    Article  PubMed  CAS  Google Scholar 

  49. Cooper LT, Hiatt WR, Creager MA, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001; 6: 235–9.

    Article  PubMed  Google Scholar 

  50. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.

    Google Scholar 

  51. Collaborative overview of randomised trials of antiplatelet therapy: II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159–68.

    Google Scholar 

  52. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet 1992; 340: 143–5.

    Article  PubMed  CAS  Google Scholar 

  53. CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996; 348: 1329–39.

    Article  Google Scholar 

  54. Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845–52.

    Article  PubMed  CAS  Google Scholar 

  55. Davies MG, Waldman DL, Pearson TA. Comprehensive endovascular therapy for femoropopliteal arterial atherosclerotic occlusive disease. J Am Coll Surg 2005; 201: 275–96.

    Article  PubMed  Google Scholar 

  56. Opie SR, Dib N. Local endovascular delivery, gene therapy, and cell transplantation for peripheral arterial disease. J Endovasc Ther 2004; 11 Suppl. 2:II151–62.

    PubMed  Google Scholar 

  57. Lenk K, Adams V, Lurz P, et al. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005; 26: 1903–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. S.R. Money has undertaken consultancies and received honoria from Otsuka America Pharmaceutical, Inc.

Author information

Authors and Affiliations

  1. Section of Vascular Surgery, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA

    Krishna Mannava & Samuel R. Money

Authors
  1. Krishna Mannava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel R. Money
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Krishna Mannava.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mannava, K., Money, S.R. Current Management of Peripheral Arterial Occlusive Disease. Am J Cardiovasc Drugs 7, 59–66 (2007). https://doi.org/10.2165/00129784-200707010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200707010-00005

Keywords

Search

Navigation